Literature DB >> 9881747

Structural features of the human salivary mucin, MUC7.

T L Gururaja1, N Ramasubbu, P Venugopalan, M S Reddy, K Ramalingam, M J Levine.   

Abstract

Human salivary mucin (MUC7) is characterized by a single polypeptide chain of 357 aa. Detailed analysis of the derived MUC7 peptide sequence reveals five distinct regions or domains: (1) an N-terminal basic, histatin-like domain which has a leucine-zipper segment, (2) a moderately glycosylated domain, (3) six heavily glycosylated tandem repeats each consisting of 23 aa, (4) another heavily glycosylated MUC1- and MUC2-like domain, and (5) a C-terminal leucine-zipper segment. Chemical analysis and semi-empirical prediction algorithms for O-glycosylation suggested that 86/105 (83%) Ser/Thr residues were O-glycosylated with the majority located in the tandem repeats. The high (approximately 25%) proline content of MUC7 including 19 diproline segments suggested the presence of polyproline type structures. CD studies of natural and synthetic diproline-rich peptides and glycopeptides indicated that polyproline type structures do play a significant role in the conformational dynamics of MUC7. In addition, crystal structure analysis of a synthetic diproline segment (Boc-Ala-Pro-OBzl) revealed a polyproline type II extended structure. Collectively, the data indicate that the polyproline type II structure, dispersed throughout the tandem repeats, may impart a stiffening of the backbone and could act in consort with the glycosylated segments to keep MUC7 in a semi-rigid, rod shaped conformation resembling a 'bottle-brush' model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881747     DOI: 10.1023/a:1006978818555

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  41 in total

1.  Large-scale purification and characterization of the major phosphoproteins and mucins of human submandibular-sublingual saliva.

Authors:  N Ramasubbu; M S Reddy; E J Bergey; G G Haraszthy; S D Soni; M J Levine
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  A sequence-coupled vector-projection model for predicting the specificity of GalNAc-transferase.

Authors:  K C Chou
Journal:  Protein Sci       Date:  1995-07       Impact factor: 6.725

4.  The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency.

Authors:  S H Shakin-Eshleman; S L Spitalnik; L Kasturi
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

5.  Determination of the site-specific O-glycosylation pattern of the porcine submaxillary mucin tandem repeat glycopeptide. Model proposed for the polypeptide:galnac transferase peptide binding site.

Authors:  T A Gerken; C L Owens; M Pasumarthy
Journal:  J Biol Chem       Date:  1997-04-11       Impact factor: 5.157

6.  Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase.

Authors:  J E Hansen; O Lund; J Engelbrecht; H Bohr; J O Nielsen; J E Hansen
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

7.  The specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase as inferred from a database of in vivo substrates and from the in vitro glycosylation of proteins and peptides.

Authors:  A P Elhammer; R A Poorman; E Brown; L L Maggiora; J G Hoogerheide; F J Kézdy
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

8.  Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core.

Authors:  J D Fontenot; N Tjandra; D Bu; C Ho; R C Montelaro; O J Finn
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

9.  Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.

Authors:  X Liu; J Sejbal; G Kotovych; R R Koganty; M A Reddish; L Jackson; S S Gandhi; A J Mendonca; B M Longenecker
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

10.  N.m.r. study of interaction between sugar and peptide moieties in mucin-type model glycopeptides.

Authors:  Y Mimura; Y Yamamoto; Y Inoue; R Chûjô
Journal:  Int J Biol Macromol       Date:  1992-10       Impact factor: 6.953

View more
  14 in total

Review 1.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

2.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

Authors:  Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2013-08-14       Impact factor: 3.467

Review 3.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

4.  The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral Streptococci and exhibits candidacidal activity.

Authors:  B Liu; S A Rayment; C Gyurko; F G Oppenheim; G D Offner; R F Troxler
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

5.  An unusual glycoform of human salivary mucin MG2.

Authors:  Rodrigo V Soares; Gwynneth D Offner; Marina A L Assis; Karine C Silva; Elton G Zenóbio
Journal:  Clin Oral Investig       Date:  2011-05-03       Impact factor: 3.573

6.  Glycosylations versus conformational preferences of cancer associated mucin core.

Authors:  J Schuman; D Qiu; R R Koganty; B M Longenecker; A P Campbell
Journal:  Glycoconj J       Date:  2000-12       Impact factor: 2.916

7.  Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.

Authors:  Mohammadreza Movahedin; Teresa M Brooks; Nitin T Supekar; Naveen Gokanapudi; Geert-Jan Boons; Cory L Brooks
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 8.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

9.  Functional analysis of the Streptococcus gordonii DL1 sialic acid-binding adhesin and its essential role in bacterial binding to platelets.

Authors:  Yukihiro Takahashi; Ayako Yajima; John O Cisar; Kiyoshi Konishi
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 10.  Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.

Authors:  Santosh Kumar Behera; Ardhendu Bhusan Praharaj; Budheswar Dehury; Sapna Negi
Journal:  Glycoconj J       Date:  2015-08-04       Impact factor: 3.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.